DIVERGIMAB Trademark

Trademark Overview

On Tuesday, July 13, 2021, a trademark application was filed for DIVERGIMAB with the United States Patent and Trademark Office. The USPTO has given the DIVERGIMAB trademark a serial number of 90826231. The federal status of this trademark filing is REGISTERED as of Tuesday, March 5, 2024. This trademark is owned by AbX Biologics, Inc.. The DIVERGIMAB trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific research services for others in the field of genetics and monoclonal antibodies; Research and development services in the field of monoclonal antibodies, namely, development of antibody-based therapeutics and discovery of reagents; Research and development services in the field of monoclonal antibodies, namely, generation of therapeutic and reagent antibodies; Genetic engineering services, namely, the production of genetically-engineered mice and monoclonal antibodies for others
divergimab

General Information

Serial Number90826231
Word MarkDIVERGIMAB
Filing DateTuesday, July 13, 2021
Status700 - REGISTERED
Status DateTuesday, March 5, 2024
Registration Number7323273
Registration DateTuesday, March 5, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 19, 2022

Trademark Statements

Goods and ServicesScientific research services for others in the field of genetics and monoclonal antibodies; Research and development services in the field of monoclonal antibodies, namely, development of antibody-based therapeutics and discovery of reagents; Research and development services in the field of monoclonal antibodies, namely, generation of therapeutic and reagent antibodies; Genetic engineering services, namely, the production of genetically-engineered mice and monoclonal antibodies for others

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 17, 2022
Primary Code042
First Use Anywhere DateTuesday, July 13, 2021
First Use In Commerce DateTuesday, July 13, 2021

Trademark Owner History

Party NameAbX Biologics, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCanton, MA 02021
Party NameAbX Biologics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCanton, MA 02021
Party NameAbX Biologics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCanton, MA 02021

Trademark Events

Event DateEvent Description
Friday, September 17, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, July 16, 2021NEW APPLICATION ENTERED
Wednesday, March 30, 2022ASSIGNED TO EXAMINER
Sunday, April 24, 2022NON-FINAL ACTION WRITTEN
Sunday, April 24, 2022NON-FINAL ACTION E-MAILED
Sunday, April 24, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 16, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 16, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, May 17, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 14, 2022NON-FINAL ACTION WRITTEN
Wednesday, June 15, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, June 14, 2022NON-FINAL ACTION E-MAILED
Tuesday, June 14, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, June 15, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 15, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 29, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 19, 2022PUBLISHED FOR OPPOSITION
Tuesday, July 19, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 13, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 14, 2023TEAS STATEMENT OF USE RECEIVED
Tuesday, February 14, 2023USE AMENDMENT FILED
Friday, March 3, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, March 8, 2023STATEMENT OF USE PROCESSING COMPLETE
Wednesday, March 22, 2023SU - NON-FINAL ACTION - WRITTEN
Wednesday, March 22, 2023NON-FINAL ACTION E-MAILED
Wednesday, March 22, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 1, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, September 15, 2023ASSIGNED TO LIE
Friday, September 15, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 15, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, January 29, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Tuesday, January 30, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, January 30, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, March 5, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, January 30, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, January 30, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 5, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

divergimab antibodies monoclonal services research namely development field others engineering genetic